values for the identification of AF subjects at low risk of stroke.
5,6
So far, a number of guidelines have focused on a categorical approach to stroke prevention, with a focus on identifying patients at moderate or high risk for oral anticoagulation. Currently, it is recommended to use CHADS 2 or CHA 2 DS 2 VASc scores to initially identify patients with nonvalvular AF at low risk of stroke who do not require antithrombotic treatment. However, the recommended scores do not incorporate all pos sible factors associated with a high thromboem bolic risk. Factors such as impaired renal func tion, obstructive sleep apnea, and echocardio graphic, biochemical, or coagulation parameters can also predict adverse thromboembolic events.
In the current issue of the Polish Archives of Internal Medicine (Pol Arch Med Wewn), Sikorska et al 7 reports their post hoc analysis of the pop ulation of patients with nonvalvular AF sched uled for pulmonary vein isolation. The authors attempted to reassess the predisposing factors for left atrial appendage (LAA) clot formation, in cluding those not included in the CHA 2 DS 2 VASc score.
7 Analyzing the results of preprocedural transesophageal echocardiography, the authors revealed an LAA thrombus or dense echo contrast in 10% of the patients despite routine anticoag ulation. Diabetes, age above 65 years, persistent AF, and renal dysfunction with an estimated glo merular filtration rate (eGFR) of less than 60 ml/ min/1.73 m 2 were predictors of an LAA throm bus. In a multivariate analysis, the only signifi cant predictors of LAA clot formation were per sistent AF and renal dysfunction with an eGFR of less than 60 ml/min/1.73 m 2 . None of the studied patients with a CHA 2 DS 2 VASc of 1 or less, eGFR of 60 ml/min/1.73 m 2 or higher, and paroxys mal AF had an LAA thrombus. The greatest area under the curve (AUC = 0.845) was achieved for Atrial fibrillation (AF) is the most common sus tained cardiac rhythm disorder, which is associ ated with a substantial risk of mortality, morbid ity, stroke, and thromboembolic complications. 1,2 A substantial evidence base is in favor of anti coagulation with oral anticoagulants, which re duce the risk of stroke in AF population by two thirds. 1,3 Not all patients with AF seem to be equal in terms of thromboembolic risk; there fore, not all of them will benefit from anticoag ulant treatment. The crucial role in the preven tion of AFrelated stroke is effective risk stratifi cation. Although several schemes have been de veloped, the currently available models have lim ited discriminatory power.
Various clinical features are associated with a higher risk of stroke, and some of them have been used to develop different risk scores proposed in the last decade. Numerous risk factors have been derived from the analyses of nonwarfarin users in clinical trials, registries, or health care facili ties. Although none of the existing 5 risk schemes such as the Atrial Fibrillation Investigators, Stroke Prevention in Atrial Fibrillation, CHADS 2 (conges tive heart failure, hypertension, age ≥75 years, di abetes, and prior stroke or transient ischemic at tack), Framingham score, and the 7th American College of Chest Physicians Guidelines, seems to be superior to others, the various guidelines rec ommend using the CHADS 2 score for the initial assessment of stroke risk. 4 Further analyses and the use of the above schemes in clinical practice allowed to identify new risk factors for stroke and led to the reeval uation of the existing risk stratification scores. Based on the previous analyses and experience, the CHA 2 DS 2 VASc scheme was proposed, comple mented with the new risk factors such as age of 65-75 years, vascular disease, and sex (female), as a tool with better positive and negative predictive combination of various biochemical, echocardio graphic, and clinical risk factors that go beyond the CHA 2 DS 2 VASc and the available bleeding scores. Although useful in some cases, the pre sented parameters should perhaps be used to fur ther refine the initial identification of patients at low risk, following which effective stroke preven tion could be offered to those with 1 or more ad ditional risk factors for stroke. Renal impairment should be strongly reconsidered as an indepen dent risk factor for stroke in stratification tools used for the evaluation of AF patients. the CHA 2 DS 2 VAScAFR score (adding 1 point for persistent AF and 1 point for renal impairment). However, the difference between the AUC for the "new" and standard schemes was not statistical ly significant (P = 0.062). These observations are largely consistent with some previous analyses. [8] [9] [10] However, other previously identified risk factors, such as congestive heart failure, left ventricular dysfunction, or hypertension, were not indepen dent predictors promoting LAA clot formation in the study population. The study by Sikorska et al 7 is particularly valuable because the authors refined the risk stratification scheme based not only on episodes of ischemic events but also on the direct visualization of a thrombus or dense echo contrast in the LAA. However, AF leads to a hypercoagulable state favoring clot formation in each part of the circulatory system, even the distant and peripheral ones, and embolization of the left atrium or the LAA, which plays a cru cial role in the development of ischemic stroke in patients with AF.
Renal dysfunction as an independent predictor of embolic complications in patients with nonval vular AF was also identified and evaluated by Pic cini et al 11 in the ROCKETAF population, and its significance was further assessed in the ATRIA co hort. The authors proposed the R 2 CHADS 2 scheme in which renal insufficiency with creatinine clear ance of less than 60 ml/min/1.73 m 2 was assigned 2 points, a power equivalent to that of previous stroke or transient ischemic attack. 11 Renal im pairment has been known as a predictor of poor prognosis in AF population not only due to the higher risk of stroke but also to a higher mortal ity rate in individuals with acute coronary syn drome and a history of arrhythmia. 12, 13 Although the assessment of stroke risk factors in patients treated with oral anticoagulants has many limitations and the stroke prediction mod els generally perform better in subjects not receiv ing the treatment, the R 2 CHADS 2 score was able to properly identify the risk of stroke in patients in the ATRIA cohort who received and did not re ceive warfarin. Sikorska et al 7 also revealed the value of their own risk stratification scheme in an ticoagulated AF patients scheduled for ablation. Impaired renal function contributes to an in creased risk of stroke through procoagulant state and inflammation but also leads to a higher bleed ing rate during anticoagulant therapy. Of the var ious proposed bleeding risk scores, renal dys function was also considered as an independent bleeding risk factor in the HEMORRH 2 AGES, HASBLED, and the most recent ORBITAF scores, which have been developed and validated in AF populations. 14 In conclusion, the current risk stratification system requires further studies to develop such scores that would allow a simple and reliable identification of individuals at risk of stroke and bleeding events. For a better understanding and more convenient application, antithrombotic risk stratification systems should be based on a
